Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
On its Q2 2026 earnings call, UnitedHealth Group highlighted a jump in adjusted EPS and operating earnings, while acknowledging ongoing cost headwinds and the need to invest in new technology, including artificial intelligence.
THE APEX TIMES
THE APEX TIMES
The stock is trading under both the 50-day and 200-day simple moving averages, a widely watched technical announcement, as the market balances declining COVID-era sales with hopes for growth from new products, pipeline execution, and recent deal activity.
THE APEX TIMES
A mid-day market wrap pointed to downside in major U.S. indexes while Taiwan Semiconductor reported results that beat expectations and outlined higher capital spending, and UnitedHealth raised its full-year outlook.
THE APEX TIMES
The discussion around UnitedHealth Group’s latest results comes as the stock remains about 25% below its all-time high, according to a recent market commentary.
THE APEX TIMES
UnitedHealth Group reported second-quarter results that beat Wall Street expectations and raised its full-year earnings outlook, sending the stock up roughly 5% in post-market trading on July 16, according to a market report.
THE APEX TIMES
A new equity research note highlighted continued progress in Johnson & Johnson’s Innovative Medicine segment, suggesting the company’s near-to-medium term product trajectory could extend into 2027.
THE APEX TIMES
Europe’s approval of an oral version of Wegovy gives Novo Nordisk another lead in the race against Eli Lilly’s weight-loss pipeline, according to reporting.
THE APEX TIMES
A market report says Eli Lilly is in talks about buying ATAI, sending ATAI’s stock sharply higher as investors wait for details on whether a deal is actually being structured.
THE APEX TIMES
The healthcare conglomerate said its second-quarter results came in above expectations and that strength in its Innovative Medicine segment, along with pipeline progress, supports an upward revision to its 2026 outlook.
